Are you planning to attend Antibody Engineering & Therapeutics Europe 2025 in Basel, Switzerland between June 10-12?

If so, make sure to connect with Abzena in booth #3 at the event. Our Director of Protein Engineering, Arron Hearn, Sr. Manager of Protein Engineering, Thomas Cornell, SVP of Commercial Strategy, Gavin Murdoch, and VP of Business Development, Patrick Haddad, will be on hand to discuss all your complex antibody engineering and development needs. Learn how our antibody design and protein engineering teams can de-risk your biologic development program.

At Abzena, we work to give you the best chance of success by combining over 24 years of protein engineering with state-of-the-art analytics services.

Don’t miss our talk on Day 2 at 11:50am where Dr Arron Hearn will be presenting a talk entitled: “An Approach to Rapidly Identify a Functional and Developable Bispecific Antibody”

Presentation Summary
Combining single function antibodies into a bi-specific or multi specific format can present unique challenges. Stoichiometry, overall layout (IgG like, asymmetrical) and affinity can all play a key role in the success of a design with the desired activity and therapeutic developability. From multiple examples, it is clear that each bispecific development program should be treated as unique and that strategies are required to identify the optimal format. Abzena has developed a screening cascade which first places a strong focus on intelligent bispecific design which considers avidity, spacing as well as the use of different technologies. In combination with in silico analysis to identify and engineer the best partners for developability we can provide screening on a minimal number of smart designs. By leveraging unparalleled expertise in antibody production, purification, analytics and functional bioassays, we can rapidly identify and advance the most promising bispecific candidates.

Conference Details:

Dates: June 10-12
Location: Basel, Switzerland
Event website: Antibody Engineering & Therapeutics Europe 2025

Complete the form below to schedule a meeting and learn how Abzena’s integrated solutions can help accelerate your biologic drug development journey.

About Abzena

Abzena is the leading end-to-end bioconjugate and complex biologics CDMO + CRO. From discovery through commercial launch, we support customers with fully integrated programs or individual services designed to de-risk and streamline the development of new treatments for patients in need. We have research, development, and cGMP facilities across locations in San Diego, CA, Bristol, PA, and Cambridge, UK.